I
ncidence of liver cirrhosis is rising worldwide with expected increases in hospital admissions and liverrelated deaths (1, 2) . Patients with cirrhosis are prone to decompensation and extra-hepatic organ failure, requiring hospital treatment and admission to the critical care unit (CCU), with high short-term mortality (3) and significant economic cost (4, 5) .
Studies describing the mortality of critically ill patients with cirrhosis suggest overall mortality ranges between 40% and 80%, with a progressive increase dependent upon the number of organ systems failing (6) (7) (8) (9) . Earlier reports noted that more than 80% of patients with two or more organs in failure by the third day of CCU admission did not survive to hospital discharge (7) .
Marked improvements in survival have been noted in patients with acute decompensation (AD) of cirrhosis and organ failure admitted to specialist liver transplant (LT) centers (10, 11) Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (http://journals.lww.com/ccmjournal). scores as patients were admitted earlier during their critical illness. In cohorts from the Royal Free Hospital, London (10) and King's College Hospital, London (11) the etiology of underlying cirrhosis was not associated with a survival difference. Furthermore, patients admitted following gastrointestinal hemorrhage had lower mortality rates compared with those with multi-organ failure. Patients with cirrhosis and significant acute organ dysfunctions have recently been classified by international consensus as suffering from the distinct clinical entity of acute-on-chronic liver failure (ACLF) (3).
The background survival for all-comers admitted to CCUs has been increasing for many years. In the United Kingdom, the present expectation is that more than 80% of patients admitted to CCUs will survive to hospital discharge. This reduced mortality trend also occurs in other patient groups where multi-organ failure are common and historical reports suggest poor survival rates, such as sepsis (12) , poly-trauma, chronic obstructive airways disease (13) , and hematologic malignancy (14) .
This increasing survival may relate to organizational improvements, protocols to reduce catheter-related bloodstream infections, and ventilator-associated pneumonia rates and training in critical care. Whether this also occurs in patients with AD or ACLF is unknown. Liver-specific treatments such as liver-assist devices have not been shown to improve outcome (15) , and use of liver transplantation for patients with cirrhosis and organ failure is rare. Prognostic pessimism has persisted on the benefit of organ support for patients with cirrhosis, especially outside LT centers (16) . Nevertheless, recent evidence from the United States suggests that survival for a hospital admission for decompensated cirrhosis is improving (17) although this study did not look at patients admitted ACLF.
Recent U.K. policy declarations reflect both the increasing numbers of patients with cirrhosis requiring treatment and potential deficiencies in care of patients with liver disease, particularly alcohol-related liver disease (ARLD) (18, 19) . It is not known whether the provision of critical care support is variable nationally in terms of numbers or patients admitted or in the resulting survival rates. It is an important moment to delineate the role of organ support in patients with cirrhosis, given the recent reevaluation of the care of these patients being undertaken (19) . Although outcomes for critically ill patients have improved markedly in recent decades, whether this is also the case for ACLF patients is less well defined outside specialist liver centers.
Here, we examine a large population of patients with cirrhosis requiring organ support in CCUs in England, Wales, and Northern Ireland. Our aim was to describe the trends in outcome over time at a national level to guide clinical decision and policy making. We also compared the effect of alcohol as an etiology on survival to hospital discharge and on whether readmission to critical care within the same hospital stay lead to similar survival rates.
METHODS

Case Mix Programme Database
The Case Mix Programme (CMP) is the national clinical audit for adult critical care in England, Wales, and Northern Ireland. The Case Mix Programme Database (CMPD) contains pooled case mix, resource use, and outcome data on consecutive admissions to participating units (both intensive care and combined intensive/high dependency units). Data are collected to precise rules and definitions, by trained data collectors, and undergo extensive local and central validation prior to pooling. Details of the data collection and validation have been reported previously (20) . The CMPD has been independently assessed to be of high quality (21) and support for the collection and use of patient-identifiable data without consent or need for institutional review board approval has been obtained under Section 251 of the National Health Service (NHS) Act 2006 (approval number PIAG 2-10(f)/2005).
Selection of Patients
Data were extracted for admissions to critical care between January 1, 1998, and December 31, 2012. Reason(s) for admission to critical care are coded using the Intensive Care National Audit and Research Centre (ICNARC) Coding Method, a hierarchical coding method specifically designed for coding reasons for admission to critical care (22) . Cirrhosis cases were identified where primary, secondary, or ultimate primary reason for admission were coded as variceal bleeding, alcoholic cirrhosis, acute alcoholic hepatitis, chronic cirrhosis (cause not defined) or portal hypertension, or where biopsy-proven cirrhosis, portal hypertension, or hepatic encephalopathy were reported in the past medical history (as per Acute Physiology And Chronic Health Evaluation [APACHE] II definitions (23) ). The hierarchical method prevents patients with noncirrhotic liver disease being included in this analysis.
Acute severity of illness was assessed with the ICNARC physiology score (25) , APACHE II Acute Physiology Score (APS), and APACHE II score (23) . The ICNARC Physiology score, APS, and APACHE II score each encompass a weighting for acute physiology defined by derangement from the normal range for 12 physiologic variables in the first 24 hours following admission to the CCU. The APACHE II score additionally encompasses a weighting for age and for severe conditions in the past medical history.
Outcome
Data were extracted for status at discharge from the CCU and status at discharge from acute hospital. Data on any readmissions to critical care within the same hospital stay were also extracted.
Analyses
Data were trended by year (1998-2012) or 5-year subgroups thereof. Case mix, outcomes, and resource use, as defined above, were described per year for each of the following groups: all cirrhosis cases, ARLD and non-ARLD, hemorrhage cases and non-hemorrhage cases, as well as the five geographical subgroups. Categorical data were summarized as number and percentage; continuous data as mean (sd) or median (interquartile range).
Odds ratios (ORs) for hospital mortality were calculated using multilevel logistic regression modeling, adjusting for age, gender, cardiopulmonary resuscitation (CPR) prior to admission, location prior to admission, IMD quintile, ICNARC score, ARLD, and year of admission with unit as a random effect.
A statistical analysis plan was agreed a priori. The analyses were performed using Stata 13 (Statacorp LP, TX).
RESULTS
Incidence
Thirty-one thousand three hundred sixty-three patients with cirrhosis were identified in the study period of 1,168,650 total admissions (2.7%). Five hundred fifty-eight patients of a total 34,024 identified admissions (1.6%) in 1998 had cirrhosis rising to 4,207 of 136,351 (3.1%) in 2012. Although coverage in the CMP did increase over this time, the extrapolated numbers show an increase from 1,450 of 87,900 (1.6%) to 4,750 of 153,600 (3.1%). These admission rates are presented per 10,000 population in Figure 1 . The mean (sd) age of patients was 52.3 (12.7) years and 64.5% were male. Table 2 and Fig. 2) . Mean (sd) highest serum creatinine for the cohort in 1998 was 176.9 (151.6) µmol/L and 148.0 (136.7) µmol/L in 2012. Highest blood lactate was only available from 2008 where it was 4.5 (4.4) mmol/L and 4.4 (4.2) mmol/L in 2012. The APACHE II risk of death for patients in 1998 was 47.6%, and this was unchanged by 2012. Therefore, the observed mortality to expected risk of death discrepancy fell markedly during the study period.
Mortality
Alcohol
Ten thousand nine hundred thirty-six patients were identified as having alcohol as the primary etiologic factor (35%). For patients with ARLD, crude hospital mortality fell from 66.7 (95% CI, 58.9-73.6) % in 1998 to 58.1 (55. Detailed data on liver assist devices was not possible within the ICNARC dataset but use of such devices (including MARS (26)) is not expected to have a significant impact on the outcome data described in this study (further details in 
Multivariate Analysis
Logistic regression analysis using hospital survival as the outcome variable and adjusting for age, sex, ICNARC score, year of admission, admission source location, index of deprivation, requirement for CPR prior to admission, and alcohol as etiology is shown in Table 3 . This gave an OR of 0.95 for year of admission (95% CI, 0.94-0.96; p < 0.001), showing a decrease in mortality over time after adjusting for confounders. Alcohol as an etiology for cirrhosis was associated with increased mortality (OR, 1.51; 95% CI, 1.42-1.61; p < 0.001). The area under receiver operating curve for the logistic regression model was 0.831 (95% CI, 0.827-0.836), the Hosmer-Lemeshow chi-square statistic was 90 (8 df, p < 0.001). Observed and predicted mortality were within ±4% across the 10 categories.
DISCUSSION
These results demonstrate that patients with cirrhosis and organ failure have substantially improved survival in the modern era of critical care provision. Most patients admitted to critical care with cirrhosis in the United Kingdom are now expected to survive.
For decades, the combination of a past medical history of cirrhosis and multi-organ failure has been perceived as having prohibitive mortality statistics and that organ support is futile (27) . Survival to hospital discharge in patients with nonhepatic reasons for admissions have been increasing recently (12) due to a combination of factors including management of sepsis, attention to prevention of nosocomial infections (e.g., ventilator-associated pneumonia and catheterrelated bloodstream infections) and organization of CCUs. Although individual factors are difficult to identify causally with decreasing mortality, the background increasing survival rate is clear.
Tertiary liver centers with access to specialist hepatology, transplantation, and hepatobiliary surgical expertise have demonstrated improved survival even when transplantation was discounted (11) . The management of portal hypertensive bleeding especially has improved significantly. Several centers have reported decreasing mortality rates in patients with or without gastrointestinal hemorrhage as the primary indication for admission (10, 11) . Both centers note a reduction in admission APACHE II score, suggesting earlier admission to CCUs prior to irreversible MOF as a useful strategy. Furthermore, both transplant centers note that alcohol is not associated with a worse mortality compared with other etiologies.
The data we present here demonstrate a different pattern. Although mortality is falling, the acuity of critical illness at admission measured by APACHE II score (and predicted risk of death) did not change significantly. Admission ICNARC score fell by a small amount over the study period, but after adjusting for this on multivariate analysis, the year-by-year fall in mortality retained statistical significance. This suggests that while earlier admission is useful to manage impending organ failure, patients should not be denied admission based on organ failure score alone and that the excess mortality associated with chronic liver disease (in addition to physiologic APACHE score) is diminishing. Our findings here confirm a more positive outlook for patients with cirrhosis and ACLF. While other authors have reported mortality rates of up to 80% in patients with ACLF-3 (3, 28) , this was in the context of care outside of CCUs, whereas all the patients in our study were cared for in CCUs. We would urge early admission to CCU to prevent irreversible organ failure occurring.
Overall, this registry study represents the largest dataset of patients with cirrhosis managed in CCUs yet reported and therefore sets the benchmark of outcomes now expected in this patient group. It companions the epidemiologic data in ALF (29) but for the first time demonstrates the improving outlook at population level for this important and more common subgroup of liver patients who require organ support.
Although there may be country-specific aspects in terms of interaction with liver transplantation services, we expect these to impact the minority of patients, given the access to LT in patients with ACLF has been limited in the past. This is because we exclude patients with ALF and transplantation is predominantly an elective procedure in patients with cirrhosis in most countries. Recent reports are challenging the dogma of whether LT is useful in patients with ACLF (30) , which may lead to higher admission rates and greater access to LT services. As the United Kingdom moves to an organ allocation system based on wait list mortality, it would be interesting to observe the impact on outcomes of patients after this change as those with organ failures will be more likely to receive an offer. In countries where Model for End Stage Liver Disease-based allocation is already in use (31), it would be interesting to see if the outcomes of patients with cirrhosis and organ failure in general is different to what we report here.
In contrast to LT units, we found that alcohol appears to be associated with an excess independent mortality risk even when confounders are addressed (although they tend to present with higher levels of organ [particularly renal] dysfunction). This discrepancy may be related to acute alcoholic hepatitis, which is associated with ongoing alcohol use and a high mortality. Our data would not allow clear delineation of this as retrospective allocation of diagnosis would require access to liver function tests, history of abstinence, imaging, or liver biopsy data. We would not suggest that patients with ARLD be denied access to CCUs based on prohibitively high mortality until the underlying reason for this higher attributable mortality is identified. The number of patients receiving LT during the index admission in this dataset would be exceedingly small. Doubt over appropriateness over the use of critical care services in actively drinking patients with ARLD may lead to delays in admission. Other investigators have noted an increased mortality in patients with ARLD who were consuming alcohol up to hospital admission (3). Of note, we see a lower incidence of ALRD compared with other etiologies in contrast to recent reports from the United Kingdom (1), which may be related to ARLD being defined from the reason for admission in the ICNARC dataset. This may represent under reporting or a reduced admission rate for ARLD outside LT centers.
This study has several limitations. We are unfortunately unable to calculate MELD, ACLF grade, or chronic liver failure Sequential Organ Failure Assessment (SOFA) scores (or apply SOFA organ failure definitions) retrospectively from these data as the CMP was set up as a general CCU dataset with a strong focus on resource use. This is a weakness that does not allow prognostic scoring systems to be compared or validated in this otherwise very large cohort. The level of detail is sufficient to give guidance on the pattern of survival over time, corrected for general ICU severity measures, which is nevertheless still useful in overcoming prognostic pessimism about admission of patients with cirrhosis to CCUs.
We are unable to demonstrate definitively which patients were listed for LT following acute admission to the CCU for organ support. However, this is likely to be a small number compared with the overall cohort. It has been demonstrated previously in analysis of the United Kingdom national database of NHS Blood and Transplant that between 2011 and 2016 only 65 patients underwent LT following an acute hospitalization with extra-hepatic organ failure (32) . At present, we are unable to demonstrate whether an unlisted patient was declined certain organ support modalities due to concerns over futility. This may occur, for example, in suspected hepato-renal syndrome, where bridging to LT was deemed futile. Further analysis will be required linking critical care and transplantation data sources to address these aspects in future studies.
The ICNARC dataset was not originally envisaged with liver disease as a primary aspect of study and so we are unable to give granular data beyond ARLD in terms of etiology. This limits the description of the major other etiologies such as viral hepatitis or non-alcohol-related fatty liver disease (NAFLD) or rarer causes such as autoimmune hepatitis. In future, NAFLD is likely to increase as a cause for cirrhosis and viral hepatitis will decrease rapidly, given the effective treatments for hepatitis C. Future studies should focus on this aspect of the increasing burden of metabolic liver disease with more detailed etiologic descriptions.
We do not have information on long-term survival as although patients may survive the critical care or hospital stay; their risk of death is still high and many will not survive the year following admission. However, these data provide further impetus for expedited transplant assessments in those patients who survive CCU admission.
In conclusion, the rising incidence of cirrhosis in the general population is reflected in increasing numbers of patients with cirrhosis admitted to CCUs. As critical care services expand, it is vital that these patients are given access to organ support as the majority will survive to hospital discharge. 
